Navigation Links
Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Date:3/19/2008

vanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Arpida contacts:

Dr Khalid Islam, President and CEO Tel: +41-61-417-96-60

Harry Welten, MBA, CFO and Senior Vice President Tel: +41-61-417-96-65

Paul Verbraeken, Head of Corporate Communications Tel: +41-61-417-96-83


'/>"/>
SOURCE Arpida Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Announces Full Year 2007 Financial Results
2. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
3. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
4. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
5. Arpida-Supported CME Symposium Available Online
6. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
7. Arpida Presents Preclinical Data on AR-2474 at ICAAC
8. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
9. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
10. Arpida Interim Results for six Months to 30 June 2007
11. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), the Vienna University ... have succeeded in embedding nearly perfect semiconductor crystals ... of producing hybrid nanowires, very fast and multi-functional ... chip in the future. The research results will ... . , Nano-optoelectronics are considered the cornerstone of ...
(Date:7/23/2014)... -- Having the right people at the table for significant ... and achieving clinical and operational goals. The 22 nd ... 20-22, 2014, in San Diego , ... experts discussing how partnerships have positively impacted their objectives. ... Executive Officer of Cape Regional Medical Center located in ...
(Date:7/23/2014)... - BioAmber Inc. (NYSE: BIOA ), ... that the underwriters of its common stock offering ... additional 420,000 shares of common stock at the ... underwriting discounts and commissions, in connection with its ... of common stock, bringing the expected net proceeds ...
(Date:7/23/2014)... China Cord Blood Corporation (NYSE: CO ) ("CCBC" or ... blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell ... catering to the mother and child segment, today announced that the ... Singapore , Hong Kong , ... the Philippines and Malaysia ...
Breaking Biology Technology:A crystal wedding in the nanocosmos 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4
... IRVINE, California and KARLSRUHE, Germany , June 16, 2010 ,The ... and the US. "Growth requires space" had already been the motto of,the last company ... ... is moving from Campbell to Irvine, California , one,of high-tech industry ...
... N.M. The world,s smallest chess board about ... pea-sized microbarbershop were winners in this year,s design contest ... at Sandia National Laboratories in mid May. The ... Sandia,s microfabrication facility, one of the most advanced in ...
... Raju Kucherlapati , Professor of Genetics at Harvard ... making—will be addressing the Controlled Release Society on the subject of ... , , ... diagnosed with non small cell lung cancer before 2003, there were ...
Cached Biology Technology:joimax(R) Moves Into Larger Premises 2Texas Tech, U of Utah win Sandia microdevice competition 2Texas Tech, U of Utah win Sandia microdevice competition 3Texas Tech, U of Utah win Sandia microdevice competition 4Personalized Treatments for Cancer Are Revolutionizing Patient Care 2Personalized Treatments for Cancer Are Revolutionizing Patient Care 3
(Date:7/23/2014)... , , , , , ... , , , , , ... changing how medical care is delivered could help prevent multiple chronic diseases and extend healthy lifespan. The idea, they argue, would be to target the... ... , , , , ... , , , , , ...
(Date:7/23/2014)... grip is affecting more than the color of people,s lawns. ... heat-loving amoeba commonly found in warm freshwater bodies, such as ... warmer than usual this year. , A 9-year-old Kansas girl ... swimming in several area lakes. The amoeba enters the body ... brain. Nose plugs can lower the odds of this rare ...
(Date:7/23/2014)... planet,s soil releases about 60 billion tons of carbon ... than that released by burning fossil fuels. This happens ... of carbon is balanced by carbon coming into the ... as well as by the underground activities of plant ... rising temperatures increase the rate of soil respiration. As ...
Breaking Biology News(10 mins):Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5Diseases of another kind 2Climate change and the soil 2
... JOLLA, CA June 1, 2010 In findings that contribute ... by Scripps Research Institute scientists has determined the structure of ... strains of human immunodeficiency virus (HIV), the virus that causes ... advance, online issue of the journal Proceedings of the ...
... release is available in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2010-06/sfeb-tio060110.php,">Chinese . ... of Medicine, in New Orleans, LA, have demonstrated ... seed oil ( Nigella sativa ) can suppress ... cell lines, in vitro. Although previous studies ...
... a global leader in forming a proactive response to climate ... adapt to the challenges and opportunities the changing climate presents. ... York City Panel on Climate Change (NPCC) and published in ... , outline the measures the city will take to proactively ...
Cached Biology News:Scripps research scientists determine structure of immune molecule that counteracts HIV strains 2Scripps research scientists determine structure of immune molecule that counteracts HIV strains 3Scripps research scientists determine structure of immune molecule that counteracts HIV strains 4Thymoquinone induced oxidative stress targets highly aggressive prostate cancers 2How New York City is preparing for climate change 2How New York City is preparing for climate change 3
Request Info...
... combines deep experience, skills and flexibility in ... team chemistry. This combination enables optimum solutions ... beyond.,With AAIBiotech, you can count on our ... than that: its the power of team ...
ZBP-89 (S-15)...
... Physical form: Lyophilized ... salts Preparation Unit Definition: ... 1.0μmole of 2-phosphoglycerate to ... pH7.4 at 25 C. ...
Biology Products: